News
FDA Oncology Approval Source Table: July 21, 2026
A source-table version of recent FDA oncology approval activity, with patient questions and the limits of what an approval headline can tell you.
Original commentary from the Cancer Explained editorial team.
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
In brief
This is a source-table version of Cancer Explained's weekly FDA oncology approval check. It is built from FDA's oncology approval notification page and is meant to separate a regulatory headline from a personal treatment decision.
Source table
| Date listed by FDA | FDA topic | What patients should check |
|---|---|---|
| July 14, 2026 | Gedatolisib with fulvestrant with or without palbociclib for HR-positive, HER2-negative metastatic breast cancer | Cancer subtype, prior treatment, hormone receptor and HER2 status, line of therapy, and side effects |
| July 14, 2026 | Selpercatinib for RET fusion-positive solid tumors | Whether RET fusion testing was done, tumor type, prior treatment, and whether this is tumor-agnostic in the exact label |
| July 10, 2026 | Pembrolizumab and enfortumab vedotin-ejfv for muscle-invasive bladder cancer | Stage, surgery plan, cisplatin eligibility, treatment goal, and neuropathy/rash/immune-toxicity counseling |
| July 9, 2026 | Subcutaneous isatuximab-irfc for multiple myeloma indications | Route of administration, schedule, combination medicines, premedicines, and infusion or injection monitoring |
| June 30, 2026 | Tregzi for matched donor transplant in adults with hematologic malignancies | Transplant setting, donor match, graft-versus-host disease context, and transplant-center eligibility |
| June 24, 2026 | Sacituzumab govitecan-hziy for first-line triple-negative breast cancer | Whether the cancer is triple-negative, treatment line, combination plan, blood counts, diarrhea, and infection precautions |
| June 24, 2026 | Palbociclib with HER2-directed therapy and endocrine therapy maintenance in HR-positive, HER2-positive metastatic breast cancer | Hormone receptor and HER2 status, maintenance goal, blood counts, and drug-interaction review |
What this does not mean
- It does not mean every patient with the cancer type listed should receive the drug.
- It does not compare the drug against every available option.
- It does not replace the full prescribing information, the FDA label, or a care-team discussion.
Questions patients can ask
- Does this approval match my exact cancer type, stage, biomarkers, and prior treatment?
- Is the approval for first treatment, later treatment, maintenance, transplant, or a specific combination?
- What side effects matter most for me, given my other conditions and medicines?
- Is there a clinical trial, standard option, or supportive-care issue I should understand before deciding?
How this article was prepared
Prepared by Cancer Explained's AI-assisted editorial system and checked against the official FDA source listed below. This article has not been reviewed by a healthcare professional unless a named reviewer is specifically shown.
Found an error, a broken source link, outdated information, or wording that feels unsafe or unclear? Report it here.